Effects and plasma proteomic analysis of GLP-1RA versus CPA/EE, in combination with metformin, on overweight PCOS women: a randomized controlled trial

What Was Tested

This randomized controlled trial paper looks at Glutathione in the context of pcos.

Polycystic ovary syndrome (PCOS) is characterized by reproductive dysfunctions and metabolic disorders.

Why It Was Studied

Registered 12 May, 2017, https://clinicaltrials.gov/ct2/show/NCT03151005 .

Who Took Part

The abstract describes 60 women taking part.

PubMed tags the participants as women only.

How the Study Was Run

In design terms this was a randomized and open-label study.

The women were allocated by chance, so the Glutathione group and the comparison group should start out alike.

Nothing was hidden in this open-label Glutathione study: the women and staff both knew the treatment.

The timeline in the abstract includes 12 weeks.

What Was Measured

Topics PubMed links to this paper include Metformin, Polycystic Ovary Syndrome, Cyproterone Acetate, Ethinyl Estradiol, Overweight, Proteomics and Luteinizing Hormone.

The authors tagged it with the keywords Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA), PCOS (Polycystic Ovary Syndrome) and Proteomics Analysis.

What This Means in Plain Language

The paper is a randomized and open-label study of Glutathione in 60 women in people with pcos over 12 weeks.

Its findings take up roughly 10 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Endocrine), a journal based in United States.

More context: the Glutathione compound page, PCOS research.